Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

NCT05971251 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Loncastuximab Tesirine and Acalabrutinib

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]